Targeting resistant lung cancer tumors with new treatment methods
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants
This study is exploring a new way to help people with non-small cell lung cancer by using a special technique to create proteins that can stop cancer from growing, with the hope of making current treatments work better and improving results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10771296 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat non-small cell lung cancer (NSCLC) by inducing specific variants of the epidermal growth factor receptor (EGFR) that can inhibit cancer growth. The method involves using antisense technology to promote the production of soluble decoy EGFR variants, which can block the signaling pathways that drive tumor growth. By targeting the underlying mechanisms of drug resistance, this approach aims to enhance the effectiveness of existing treatments and potentially improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have shown resistance to current EGFR-targeted therapies.
Not a fit: Patients with lung cancer that is not driven by EGFR mutations or those who are not resistant to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with drug-resistant lung cancer.
How similar studies have performed: Other research has shown promise in using similar approaches to target cancer signaling pathways, indicating potential for success in this novel application.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Cartegni, Luca — Rutgers Biomedical and Health Sciences
- Study coordinator: Cartegni, Luca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.